AU - Lyman, David TI - B cell Therapy to Treat an Axonal Neuropathy in Mixed Connective Tissue Disease PT - JOURNAL ARTICLE TA - gums-cjns JN - gums-cjns VO - 3 VI - 1 IP - 1 4099 - http://cjns.gums.ac.ir/article-1-154-en.html 4100 - http://cjns.gums.ac.ir/article-1-154-en.pdf SO - gums-cjns 1 ABĀ  - The B cell is a vital contributor to humoral immunity. The B cell-specific antigen CD20 is expressed during B cell development, starting at the pre-B cell level and persists through B cell differentiation, but is lost during terminal differentiation to plasma cells. Rituximab is a monoclonal antibody that destroys both normal and malignant B cells that have CD20 on their surfaces and is therefore used to treat diseases characterized by excessive B cells, overactive B cells, or dysfunctional B cells. The connective tissue diseases and vasculitis mediated by B cell may cause various disorders of the peripheral nervous system especially axonal neuropathy. B cell–directed therapies may represent a promising new treatment for autoimmune axonal neuropathies. CP - IRAN IN - LG - eng PB - gums-cjns PG - 46 PT - Review YR - 2017